000623:SZSEJilin Aodong Pharmaceutical Group Co., Ltd. Analysis
Data as of 2026-03-14 - not real-time
Latest Price
Risk Level: Medium
Executive Summary
Jilin Aodong Pharmaceutical trades around CNY 18.7, comfortably above its 20‑day SMA (18.75) but below the 50‑day SMA (19.53), indicating a modest short‑term pull‑back. The stock’s PE of 8.58 is dramatically lower than the industry average of 26.18, and the PB of 0.72 suggests a sizeable valuation cushion. A dividend yield of 2.67% with a payout ratio under 25% appears sustainable given the company’s strong cash position (CNY 3.11 bn) that exceeds its debt (CNY 2.25 bn). Technicals show a neutral RSI (44) and a bullish MACD histogram (+0.048), while volume remains stable, supporting a hold stance in the near term. Volatility over the past 30 days is high at ~28%, yet the beta is very low (≈0.2), implying limited systematic risk. Over the medium to long horizon, the combination of undervalued multiples, dividend income, and low market‑wide risk makes the stock an attractive value play.
Market Outlook
Short Term
< 1 yearKey Factors
- Price near immediate support at CNY 18.26
- Bullish MACD histogram indicating slight upward momentum
- Stable trading volume supporting liquidity
Medium Term
1–3 yearsKey Factors
- Significant valuation discount (PE 8.58 vs industry 26.18)
- Attractive dividend yield with low payout ratio
- Low systematic risk reflected by beta around 0.2
Long Term
> 3 yearsKey Factors
- Enduring demand for pharmaceuticals in China
- Sustainable cash generation despite high debt‑to‑equity
- Undervaluation relative to peers offering upside potential
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.